Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically
The uploaded content will be moved to this newly created album. You must create an account or sign in if you want to edit this album later on.
Error report
Podijeli
__privacy_notes__
Koristimo vlastite kolačiće i kolačiće trećih strana kako bismo poboljšali vaše iskustvo pregledavanja i naše usluge. Ako nastavite koristiti našu web stranicu, podrazumijeva se da to prihvaćate politika kolačića.